Table 3.
Phase 1b GO30140 study (arm A): objective response and durability of response [modified from 37]
| Arm A: Atezo + Beva (n = 104) | ||||
|---|---|---|---|---|
| IRF RECIST v1.1 | IRF HCC mRECIST | INV RECIST v1.1 | ||
| Confirmed ORR | 37 (36%) (26–46) | 41 (39%) (30–50) | 34 (33%) (24–43) | |
| CR | 12 (12%) | 16 (15%) | 3 (3%) | |
| PR | 25 (24%) | 25 (24%) | 31 (30%) | |
| DCR | 74 (71%) | 74 (71%) | 78 (75%) | |
| Ongoing response | 28 (76%) | 28 (68%) | 24 (71%) | |
| Median DOR, months | NE (11.8 to NE) | NE (11.8 to NE) | NE (11.7 to NE) | |
| DOR range, months | >1.6 to >31.0 | >1.6 to >31.0 | >3.5 to >31.0 | |
| ≥9 months | 20 (54%) | 25 (61%) | 21 (62%) | |
| ≥12 months | 11 (30%) | 11 (27%) | 12 (35%) | |
Median duration of follow-up: 12.4 months. Figures are presented as n (%) or n (%) (95% CI). Atezo, atezolizumab; Beva, bevacizumab; IRF, independent review facility; HCC, hepatocellular carcinoma; INV, investigators; NE, not estimable; ORR, objective response rate; CR, complete response; PR, partial response.